Ropivacaine Use in Femoral Nerve Block; What is the Minimal Effective Analgesic Concentration (MEAC 90)
Study Details
Study Description
Brief Summary
The aim of this study is to determine the minimal effective ropivacaine concentration required to provide adequate analgesic femoral nerve block in 90% of patients (MEAC90)
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
Phase 4 |
Detailed Description
-
Before induction of GA, all patients will receive sciatic, obturator, lateral femoral cutaneous and femoral nerve blocks.
-
The femoral nerve block will be performed using 15ml of ropivacaine which concentration relied on the response of the previous patient.
-
Based on biased-coin design up-down sequential method: when a patient has a negative response, the next patient will receive a concentration 0.01% w/v higher. However if he has a positive response, the next patient will be randomized to receive either the same ropivacaine concentration or a concentration 0.01% w/v less.
-
Patients with pain free recovery will be considered to have positive response.
-
Patients' responses will be analyzed to calculate the MEAC90
Study Design
Outcome Measures
Primary Outcome Measures
- effective analgesic femoral nerve block [in recovery unit (one hour after surgery)]
postoperative pain. it will be assessed using numerical rating scale (NRS). NRS, 0 = no pain; 10 = worst pain imaginable; if NRS ≥ 3, pain (ineffective block) is considered, other wise a successful block will be considered.
Eligibility Criteria
Criteria
Inclusion Criteria:
- Patients, who are scheduled for knee ligament reconstruction
Exclusion Criteria:
-
<18 y,
-
ASA physical class greater >III
-
BMI >40 has any contraindication for medications or techniques used in the study
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Healthpoint Hospital | Abu Dhabi | United Arab Emirates | 112308 |
Sponsors and Collaborators
- Healthpoint Hospital
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- MF2467-2021-14